NCT03520660 2026-03-11
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
Clinical Trials
10 trialsNCT03903185 2023-08-22
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
Ain Shams University
Phase 1/2 Completed
NCT02868242 2020-03-02
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy
Gilead Sciences
Phase 2 Completed
NCT03551444 2018-06-11
CAUTIOUS
Ain Shams University
Phase 3 Unknown
NCT02959359 2017-08-07
DAA in the Risk of Recurrence After Curative Treatment of HCC
Taipei Veterans General Hospital, Taiwan
Phase 4 Withdrawn
NCT02771405 2016-05-13
FRI-STC
National Hepatology & Tropical Medicine Research Institute
Phase 3 Unknown
NCT00630084 2015-09-04
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Completed
NCT00375661 2015-09-02
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
Kyoto University Hospital
Phase 4 Completed
NCT00502086 2011-02-11
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
Catalysis SL
Phase 3 Completed
NCT00834860 2010-02-15
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4 Unknown